Twenty years of evolution of CML therapy: how the treatment goal is moving from disease to patient
D Russo, M Malagola, N Polverelli… - Therapeutic …, 2023 - journals.sagepub.com
The introduction of imatinib in 2000 opened the era of tyrosine kinase inhibitors (TKIs) for
CML therapy and has revolutionized the life expectancy of CML patients, which is now quite …
CML therapy and has revolutionized the life expectancy of CML patients, which is now quite …
Complete molecular remission (CMR 4.5) of CML is induced faster by dose–optimized imatinib and predicts better survival-results from the randomized CML-study IV
R Hehlmann, M Lauseker, B Hanfstein, MC Müller… - 2012 - ashpublications.org
Abstract 67 Dose optimized imatinib (IM) at doses of 400–800mg has been shown to induce
faster and deeper cytogenetic and molecular–responses than standard IM (400mg/day) …
faster and deeper cytogenetic and molecular–responses than standard IM (400mg/day) …
Current treatment concepts of CML
AA Leitner, A Hochhaus… - Current Cancer Drug …, 2011 - ingentaconnect.com
The elucidation of the triggering molecular mechanism of chronic myeloid leukemia gave
rise to the development of imatinib, a tyrosine kinase inhibitor and a prototype of target …
rise to the development of imatinib, a tyrosine kinase inhibitor and a prototype of target …
Initial treatment for patients with CML
JM Goldman - ASH Education Program Book, 2009 - ashpublications.org
For adult patients who present with chronic myeloid leukemia (CML) in chronic phase it is
now generally agreed that initial treatment should start with the tyrosine kinase inhibitor (TKI) …
now generally agreed that initial treatment should start with the tyrosine kinase inhibitor (TKI) …
Imatinib is still recommended for frontline therapy for CML
A Hantel, RA Larson - Blood Advances, 2018 - ashpublications.org
Imatinib is still recommended for frontline therapy for CML | Blood Advances | American
Society of Hematology Skip to Main Content Advertisement Umbrella Alt Text Umbrella Alt Text …
Society of Hematology Skip to Main Content Advertisement Umbrella Alt Text Umbrella Alt Text …
The argument for using imatinib in CML
S Claudiani, JF Apperley - Hematology 2014, the American …, 2018 - ashpublications.org
June 2018 was the 20th anniversary of the clinical use of the first tyrosine kinase inhibitor
(TKI), imatinib, for chronic myeloid leukemia. Since then, the change in prognosis for …
(TKI), imatinib, for chronic myeloid leukemia. Since then, the change in prognosis for …
How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: unmet needs, pitfalls and …
M Breccia, G Alimena - Cancer letters, 2012 - Elsevier
Imatinib has revolutionized treatment strategies for chronic myeloid leukemia patients: long-
term overall survival was reported to be up to 80% at 8years of follow-up in respondent …
term overall survival was reported to be up to 80% at 8years of follow-up in respondent …
CML: the good, the better, and the difficult choices
J Cortes - Blood, The Journal of the American Society of …, 2012 - ashpublications.org
This study is the sequel to a trial where they first compared imatinib standard-dose to
imatinib high-dose. The results of the second portion of the study presented here show an …
imatinib high-dose. The results of the second portion of the study presented here show an …
Real-world Management of CML: Outcomes and Treatment Patterns
N Held, EL Atallah - Current Hematologic Malignancy Reports, 2023 - Springer
Abstract Purpose of Review Chronic myeloid leukemia (CML) is a disease that previously
signified a poor prognosis, but treatment options and outcomes have improved over the last …
signified a poor prognosis, but treatment options and outcomes have improved over the last …
CML—where do we stand in 2015?
R Hehlmann - Annals of hematology, 2015 - Springer
CML—where do we stand in 2015? Page 1 EDITORIAL CML—where do we stand in 2015?
Rüdiger Hehlmann Received: 28 January 2015 /Accepted: 28 January 2015 © Springer-Verlag …
Rüdiger Hehlmann Received: 28 January 2015 /Accepted: 28 January 2015 © Springer-Verlag …